Garry E. Menzel, President and CEO at TCR2 THERAPEUTICS INC. (TCRR), sold 23,416 shares at $1.37 ($32K) on 2022-12-05, disclosed to the SEC on 2022-12-07.
Scheduled sale ($32k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.37 | 8,530 | $12K | 36.8% |
| 2 | $1.35 | 14,886 | $20K | 63.2% |
| Total | $1.36 avg | 23,416 | $32K | 100% |
| Filing → |
| TCRR | SELL | 2022-12-09 | $23K | — | Filing → |
| TCRR | SELL | 2022-12-05 | $12K | — | Filing → |